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Abstract
Background: Unresectable cholangiocarcinoma (CCA) has a dismal prognosis. Initial studies of ortho-
topic liver transplantation (OLT) alone for CCA yielded disappointing outcomes. The Mayo Clinic dem-
onstrated long-term survival using neoadjuvant chemoradiotherapy followed by OLT in selected patients
with unresectable CCA. This study reports the Irish National Liver Transplant Programme experience of
neoadjuvant therapy and OLT for unresectable CCA.
Materials and Methods: Twenty-seven patients with CCA were selected for neoadjuvant chemoradio-
therapy in a single centre from October 2004 to September 2011. Patients were given brachytherapy,
external beam radiotherapy and 5-fluorouracil (5-Fu), followed by liver transplantation if progression free
(20 patients).
Results: Twenty progression-free patients after neoadjuvant therapy underwent OLT. Hospital mortality
was 20%. Of the 16 patients who left hospital, survival rates were 94% and 61% at 1 and 4 years. Seven
patients developed recurrent disease and died at intervals of 10–58 months after OLT, whereas 9 are
disease free with a median follow-up of 37 months (18–76). Predictors of disease recurrence were a
tumour in explant specimen and high CA 19.9 levels.
Discussion: In selected patients with unresectable CCA, long-term survival can be achieved using
neoadjuvant chemoradiotherapy and OLT although short-term mortality is high. Prospective international
registries may aid patient selection and refinement of neoadjuvant regimens.
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Introduction
Cholangiocarcinoma occurs in two principal settings. First, it
may arise ‘de novo’ in patients with no underlying biliary tract
pathology. In this situation, it most commonly occurs in the
hilar region (50–60% of cases), at the confluence of the right
and left hepatic ducts (i.e. Klatskin tumour).1 Second, it may
arise in the setting of pre-existing primary sclerosing cholangitis
(PSC).2 In either case, the surgical options are limited and
the surgical outcomes are disappointing. In the case of hilar
cholangiocarcinoma (hilar CCA) barely 25% of patients are suit-
able for surgical resection, which usually involves an extended
hepatectomy.3 Furthermore, the 5-year survival is just 25–30% in
most series.4–6 In the case of PSC cholangiocarcinoma (PSC
CCA) the surgical options are even more limited because of the
underlying liver disease and because of the frequently multifocal
nature of the tumour.2
Almost 20 years ago, the Mayo Clinic proposed a novel strategy
of neoadjuvant chemo radiotherapy followed by liver transplan-
tation for unresectable cholangiocarcinoma.7 This was based on
a concept originally proposed at the University of Nebraska8
and has become widely known as the ‘Mayo Protocol’. The Mayo
Protocol involves external beam radiotherapy (40–45 Gy delivered
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over 3 weeks), followed by transcatheter brachytherapy at a dose
of 20–30 Gy as a single dose. Infusional 5-fluorouracil (5-FU) is
given during the radiotherapy. The patients are maintained on
oral capecitabine while awaiting orthotopic liver transplantation
(OLT). The Mayo Clinic group have published regular updates on
the results of this treatment strategy9–11 and have most recently
published an update on 136 patients with 1-, 3- and 5-year sur-
vivals of 92%, 81% and 74%, respectively.11 In spite of these truly
outstanding results, this treatment strategy has not yet been
widely adopted around the world.
In 2004, based on early reports from the Mayo Clinic, our unit
undertook a pilot study of a neoadjuvant therapy/liver transplan-
tation regime for carefully selected patients with unresectable
cholangiocarcinoma. Our programme is a single centre national
programme, serving a population of 4.2 million, which has per-
formed more than 750 liver transplants and currently performs
60–65 liver transplant procedures each year.
Patients and methods
Patient group
Twenty-seven patients at a single National Liver Transplant
Centre were considered for neoadjuvant chemo radiotherapy
followed by OLT between October 2004 and September 2011.
There were 25 males and 2 females, with an age range of 24–67
years. All patients had a diagnosis of either unresectable ‘de
novo’ hilar cholangiocarcinoma (hilar CCA) or cholangiocarci-
noma arising in the setting of underlying primary sclerosing
cholangitis (PSC CCA).
The patients with hilar CCA were deemed unresectable based
on radiological appearances and after assessment by at least two
Hepato-Pancreato-Biliary surgeons and formal presentation/
discussion at our institutional Multidisciplinary Team (MDT)
meeting. The patients with PSC CCA were considered based on
the emergence of a dominant or suspicious stricture in patients
with established PSC.
Assessment
The preliminary work up of the patients was designed to: (i)
determine the size of the primary tumour mass; (ii) establish a
definite tissue diagnosis; and (iii) exclude spread beyond the
immediate locoregional area. Patients were excluded if they had a
tumour mass greater than 3 cm on cross-sectional imaging. A
definitive tissue diagnosis was attempted by either histological
(endoluminal biopsy) or cytological (biliary brushing) examina-
tion after percutaneous drainage. All tissue specimens were
examined by an experienced biliary pathologist and reviewed at
the MDT meeting. A computed tomography (CT) scan of thorax,
abdomen and pelvis was used to exclude systemic spread of the
tumour and to determine the degree of any vascular involve-
ment. Vascular encasement of the hepatic artery was not a con-
traindication to the treatment protocol. Patients were excluded
if they had an open or transperitoneal biopsy of the tumour
mass or if they had previous attempted surgical treatment or
chemotherapy.
Neoadjuvant treatment
The patients selected for the treatment protocol then proceeded to
the neoadjuvant treatment regime. Patients received a single dose
of brachytherapy, delivered by a percutaneous transhepatic cath-
eter. The typical dose was 7.5 Gy prescribed at a distance of 1 cm
from the central plane. The maximum active length was 12 cm.
The isotope was high-dose rate Iridium 192 mounted on a retract-
able wire (Gammamed system) and the treatment times varied
from 10–20 min. The patients also received external beam radio-
therapy, 45–55Gy (usually 50G y), delivered at a dose of 2 Gy per
day, for 5 days per week over 5 weeks. Treatment planning CT
scans were used and the gross target volume consisted of any
radiologically visible tumour. The clinical target volume included
the gross target volume plus the hilar lymph nodes and, in some
instances, the adjacent para-aortic nodes. The planning target
volume included the clinical target volume plus 1 cm. Three-
dimensional conformal techniques were used to design and
deliver the radiotherapy using minimum energy of 6 MV. Stand-
ard dose volume constraints were used for the organs at risk. The
patients also had a 5-FU infusion of 1000 mg/m2/day for 4 days
during week 1 and again during week 5 of the external beam
radiotherapy. Finally, they had maintenance capecitabine at a dose
of 2000 mg/m2/day (in two divided doses) for 2 weeks out of every
3 while on the waiting list for OLT.
Final assessment
On completion of neoadjuvant treatment, the patients underwent
either a formal laparotomy (preferably) or a laparoscopy. Excision
biopsy of a lymph node in the hepatic pedicle was performed and
any other suspicious or enlarged nodes were also excised for biopsy.
A full examination of the peritoneal surface was also performed
and biopsy of any suspicious lesions was performed. The liver was
carefully examined by palpation and by per-operative ultrasonog-
raphy. Finally, peritoneal washings were obtained for cytological
examination. No attempt was made to biopsy the tumour mass.
The patients were then formally presented at our Liver Unit
MDT and were placed on the waiting list for OLT if they had no
exclusion criteria and were otherwise fit for transplantation. They
were maintained on oral capecitabine as described above while on
the waiting list. CT scans of the thorax, abdomen and pelvis were
repeated if patients were more than 4 months on the waiting list.
Surgical treatment
At liver transplantation, a preliminary careful inspection of the
peritoneum and liver was performed and a frozen section biopsy
was undertaken for any suspicious lesions. The OLT was a stand-
ard caval replacement procedure. The portal vein was taken low,
near the first part of the duodenum. Arterial reconstruction was
performed using an iliac artery conduit from the infra renal ante-
rior aorta, because of potential radiation damage to the native
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hepatic artery. Biliary drainage was by Roux-en-Y hepaticojeju-
nostomy. Post-operatively, patients were maintained on standard
dual therapy of tacrolimus and steroids. Tumour surveillance was
by CT thorax, abdomen and pelvis (CT-TAP) and carbohydrate
antigen 19-9 (CA19-9), performed every 6 months for 2 years and
annually thereafter.
Statistical analysis
Survival figures were analysed for 1-year actual survival and 2-, 3-
and 4-year actuarial survival (Kaplan–Meier). The numbers were
too small to conduct 5-year survival analysis. Analysis of factors
influencing outcome was performed using the chi-square test
and Fisher’s exact test. Statistical significance was considered at
P < 0.05 where numbers were sufficient to allow meaningful sta-
tistical analysis.
Results
Of the 27 patients who were initially considered for the treatment
regime, 7 were subsequently excluded because of disease extent or
disease progression whilst undergoing neoadjuvant treatment or
whilst awaiting OLT. These 7 patients are not considered further in
this report. A total of 20 patients therefore proceeded to OLT and
are the subjects of this study. There were 19 males and 1 female,
age range 24–67 years.
Six patients (30%) required simultaneous pancreatico-
duodenectomy (Whipple’s operation) either because of radiation
effect (3 patients) or because of disease location/extent in PSC-
CCA patients (3 patients). The need to perform a Whipple’s pro-
cedure was determined at the time of surgery. Three patients
(15%) required re-transplantation at 2 days, 29 days and 41 days
after initial OLT. The indications for re-transplantation were
hepatic artery thrombosis (2 patients), and portal vein thrombosis
(1 patient). The median duration of surgery was 5 h (range 3.7–
8.4) and the median hospitalisation was 18 days (12–109).
There were 4 hospital deaths at 3 days, 35 days 55 days and 109
days after OLT (20% hospital mortality). The causes of hospital
death are summarised in Table 1. Two of the 4 deaths (50% of the
hospital mortality) were patients who had simultaneous OLT plus
Whipple’s operation. The other 2 deaths were patients who
required re-transplantation. Therefore, all of the hospital mortal-
ity occurred in patients who either required simultaneous Whip-
ple’s operation or who required re-transplantation.
Sixteen patients (80%) left hospital alive. Among this group, 7
patients subsequently developed recurrent disease and died at 10,
12, 15, 17, 41, 52 and 58 months after OLT (Fig. 1). The remaining
9 patients (56%) are currently alive and disease free at a median 37
months after OLT (Fig. 1). The survival figures for the entire
group of 20 patients are 75% at 1 year (actual), and 60%, 60%, and
51% at 2, 3 and 4 years (actuarial). The survival figures for the 16
patients who left hospital (i.e. censored for hospital deaths) were
94% at 1 year (actual) and 73%, 73% and 61% at 2, 3 and 4 years
(actuarial) (Fig. 2).
Six patients in the group were over 60 years of age at the time of
OLT and a further 5 patients were aged 50–59 years. The 4 peri-
operative deaths all occurred among the 11 patients who were
over 50 years of age. However, among the 16 patients who left
hospital alive, the survival figures were not influenced by age over
50 years or under 50 years.
There were 4 patients with hilar CCA and 16 patients with PSC
CCA. All 4 patients with hilar CCA developed recurrent disease
and died at 10, 17, 41 and 58 months after OLT. Among the PSC
CCA patients (16 patients) there were the 4 hospital deaths and 3
Table 1 Causes of hospital mortality
Operation Post-operative course/cause
of death
Survival
time (days)
OLT Primary graft non-function
Retransplant
Arrest
3
OLT and Whipples DIC/multiorgan failure 35
OLT and Whipples Hepatic artery thrombosis 55
OLT Hepatic artery thrombosis
Retransplant
Pancreatic leak
Hepatic artery bleed
Multiple laparotomies
Sepsis
Haemorrhage
109
Figure 1 Mortality and survival data
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deaths from recurrent disease at 12, 15 and 52 months post-OLT.
There are 9 PSC CCA patients alive and disease free at 18–76
months (median 37 months) after OLT.
All except two patients had a definite tissue diagnosis of CCA
prior to undergoing the neoadjuvant treatment protocol (either
histology or cytology). The two patients without a definite diag-
nosis had highly suspicious imaging combined with high CA19-9
(>100). Both of these patients had a tumour in the explant speci-
men and subsequently developed recurrent disease and died at 12
and 15 months. It can therefore be concluded that all patients in
this series had a definite diagnosis of malignancy, either by
histology/cytology or by subsequent disease evolution.
Although brachytherapy was considered to be an important
part of the ‘intention-to-treat’ strategy, in fact only 11 patients
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Figure 2 Kaplan–Meier survival curves (a) for all 20 patients; and (b) for 16 patients who left hospital alive. Number of patients alive at each
time point
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received brachytherapy. For nine patients, it was not possible, for
technical reasons, to place the transhepatic catheter or to position
the iridium wire in the appropriate position. Of the 16 patients
who left hospital alive, 8 had received brachytherapy (of whom 3
are alive and disease free, 37%) whereas 8 did not receive brachy-
therapy (of whom 6 are alive and disease free, 75%) (Fig. 3).
Seven patients were less than 1 month on the waiting list for a
liver transplant and 7 patients were more than 3 months on the
waiting list (longest wait was 217 days, i.e. 7 months). There was
no difference in recurrence rates or survival between those with a
short waiting time and those with prolonged waiting times
(Fig. 4).
Among the 20 patients, there were 9 patients who had a viable
tumour in the explant specimen and 2 patients had positive lymph
nodes (in spite of negative nodes at staging laparotomy). All
except 2 of the 9 patients with a viable tumour had received
brachytherapy. Among the 16 patients who left hospital alive, 7
had a viable tumour in the explant specimen. Of these, 6 devel-
oped a recurrent tumour and died at 12, 15, 17, 41, 52 and 58
months. Just 1 patient with a viable tumour (and positive lymph
nodes) is currently alive and well at 66 months post-OLT.
Pre-operative CA19-9 levels are available on 14 of the 20
patients. Six patients had CA19-9 levels >100 and 8 patients had
CA19-9 levels < 100. Patients with high CA19-9 levels were more
likely to have a tumour in the explant specimen (5 of 6 patients)
and to develop recurrent disease and die. Patients with low
CA19-9 levels were more likely to have no residual tumour in the
explant specimen (8 of 8 patients) and to be alive and disease free
(7 of 8 patients) (Fig. 5). Patients who developed recurrent disease
and died (7 patients) all had a residual viable tumour in their
explant specimen and elevated CA19-9 levels. Five of these 7
patients had received brachytherapy and 4 of the 7 patients were
waiting less than 1 month for OLT. In contrast, among the 9
patients who are currently alive and well, 8 had no residual
tumour in the explant specimen and 7 out of 8 patients (one
missing value) had low CA19-9 levels. Only 3 of these 9 patients
had received brachytherapy and 5 of the 9 patients were waiting
more than 3 months for OLT.
Discussion
Barely 25–30% of patients with hilar CCA are surgically resect-
able.3 Furthermore, the results of a surgical resection for hilar
CCA are characterized by high hospital mortality, high complica-
tion rates and poor long-term survival.11 When CCA occurs in the
setting of PSC, the surgical options are even more limited and the
results are likewise poor.12 For these reasons, a liver transplanta-
tion appears to present an attractive concept for these patients
because it allows radical resection with a guaranteed tumour-free
resection margin and it also treats the underlying PSC when
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present. In the early years of liver transplantation (1960s and
1970s), cholangiocarcinoma was a relatively frequent indication
for liver transplantation. However, the results did not live up to
expectation and recurrence rates were unacceptably high.13 As a
result, cholangiocarcinoma became a contraindication for liver
transplantation in most centres.14 The emergence of neoadjuvant
chemoradiotherapy has rekindled interest in the role of liver
transplantation for CCA and this approach has been largely pio-
neered by the Mayo Clinic group.15,16 The present study of a small
group of patients with unresectable CCA, treated by neoadjuvant
chemoradiotherapy followed by liver transplantation in a single
national centre, has shown superior results to those of surgical
resection. Overall 1-, 3- and 4-year survivals were 75%, 60% and
51%, respectively. However, when the data were censored for hos-
pital deaths, the disease-related 1-, 3- and 4-year survivals were
94%, 73% and 61%, respectively.
The results published on a regular basis by the Mayo Clinic
group have shown significantly better outcomes than reported in
the present series. From the time of the first report in 2000, there
were excellent results.7 The second report, in 2004,9 showed 92%,
82% and 82% 1-, 3- and 5-year survivals among 38 patients. By
2008, the series had grown to 111 patients with 96%, 83% and
72% 1-, 3- and 5-year survivals.10,17 At that time, they reported just
15 recurrences in 111 patients. The latest updates, in 2012, show
92%, 81% and 74% 1-, 3- and 5-year survivals among 136
patients.11,18 Furthermore, the latest report includes patients from
11 other institutions in the United States, a cumulative experience
of 214 patients. Considering that the Mayo Clinic contributed 131
patients to this series, it is clear that most of the other 11 centres
contributed very small numbers of patients.18 One of the most
perplexing features of this treatment strategy for unresectable
cholangiocarcinoma is that it has not been widely adopted around
the world, in spite of the excellent reports from the Mayo Clinic
group and other US centres.19
Part of the reason for our poorer results (as compared with the
Mayo Clinic) undoubtedly relates to high hospital mortality
(20%). This is largely accounted for by the high percentage of our
patients (30% versus 9% in latest Mayo report18) who required
Whipple’s operation (2 of our 4 hospital deaths had Whipple’s
operation plus OLT) and the need to perform re-transplantation
(2 of our 4 hospital deaths). Most of our simultaneous Whipple’s
operations were performed early in our series because of a radia-
tion effect around the hepatic pedicle, making safe dissection in
this area impossible. Subsequent alterations in the radiotherapy
administration protocol have resulted in less radiation effect in
this region and a lower requirement for performing Whipple’s
procedure. On the other hand, it should be noted that our 2
longest survivors (66 and 76 months) were PSC CCA patients who
had a simultaneous Whipple’s procedure plus OLT.
In our series, the results of neoadjuvant chemo radiotherapy
followed by liver transplantation appear to have been worse for
patients with hilar CCA than for patients with PSC CCA. The 4
patients with hilar CCA all developed recurrent disease and sub-
sequently died. However, 2 of these patients survived 41 and 58
months. These numbers are certainly too small to make any valid
conclusion. On the other hand, among the 12 hospital survivors
with PSC CCA, only 3 patients developed recurrent disease and 9
remain disease free at a median of 37 months after treatment.
All of the patients in our series had a definite tissue diagnosis of
cholangiocarcinoma. In the vast majority of patients (18 of 20
patients) there was a definite diagnosis prior to commencing neo-
adjuvant chemo radiotherapy, either by endoluminal biopsy/
histology or by biliary brushings/cytology. Two patients did not
have a definite tissue diagnosis prior to neoadjuvant therapy but
had characteristic radiological appearances together with mark-
edly elevated CA19-9 levels. In fact, both of these patients had a
tumour in the explant specimen and developed recurrent disease
and died from disseminated cholangiocarcinoma at 12 and 15
months, indicating that they did indeed have definite cholangi-
ocarcinoma from the outset. In the Mayo Clinic series, barely 50%
of the patients had a definite tissue diagnosis before treatment.
However, approximately one-half of those without a tissue diag-
nosis had subsequent proof of diagnosis, either on explant histol-
ogy or by disease progression.18 Furthermore, the Mayo results are
still excellent even when the patients without a tissue diagnosis are
excluded from the analysis.
Although brachytherapy was an integral part of our neoadju-
vant regime, in fact, 9 patients (45%) did not receive brachy-
therapy but still continued on the treatment protocol. This was
because of technical problems in patients with PSC causing an
inability to place a percutaneous transhepatic catheter in the
appropriate bile duct or place the iridium pellet in the correct
location. These patients just received external beam radiotherapy
plus chemotherapy. Contrary to expectation, this did not have a
CA 19.9 > 100: 6 patients
1. Dead 52
2. Dead 58 
3. Dead 15
4. Dead 1.2
5. Dead 17
6. Alive 17 
CA 19.9 < 100: 8 patients
1. Alive 76
2. Alive 41 No
3. Alive 38 
4. Alive 35
5. Alive 28
6. Alive 36 No
No7. Alive 26
8. Dead 1.8 No
Status Time (Months) Tumour in explant
Yes
Yes
Yes
Yes
Yes
No
No
No
No
No
Figure 5 Relationship of carbohydrate antigen 19-9 (CA19-9) levels
to survival status and to presence of a viable tumour in explant
specimen
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negative impact on the outcome. In fact, of the 16 hospital survi-
vors, 8 had received brachytherapy (among whom there were 5
recurrences and deaths, 61%) and 8 did not receive brachytherapy
(with only 2 recurrences and deaths, 25%). Again, the numbers are
too small to allow statistical analysis but there certainly are ques-
tions to answer about the role of brachytherapy in these patients.
Although the Mayo group give brachytherapy, they also state that
brachytherapy is technically difficult and resource intensive and
that exact placement of the Iridium beads/pellet can be challeng-
ing. In their analysis, they conclude that there is no added benefit
in giving brachytherapy compared with external beam radio-
therapy alone.18
Another unexpected finding in our series is that the time on the
transplant waiting list did not appear to affect the likelihood of
recurrence and death. Patients who were waiting 1 month or less
on the transplant waiting list appear to have fared no better than
patients who were waiting more than 3 months on the waiting list.
In fact, the 2 longest survivors in our series were waiting more
than 6 months on the waiting list.
The single most important factor in determining long-term
outcome in our series appears to be the presence or absence of a
residual tumour in the explant liver specimen. Of the 16 patients
who left hospital, 7 had a residual tumour in the explant specimen
and 9 had a complete pathological response with no residual
tumour in the specimen. Among the 7 patients with a residual
tumour, 6 developed recurrent disease and died and just 1 patient
is currently alive and disease free (at 66 months). On the other
hand, among the 9 patients with no residual tumour, no patient
has developed recurrent disease, although one patient died from
unrelated causes. Although this prognostic indicator is very
important, it is of limited usefulness because the information only
becomes available after the treatment (including OLT) has been
completed. It would indeed be very useful if there was a predictive
indicator for a tumour in the explant specimen. In our series, the
CA19-9 was highly predictive of a tumour in the explant speci-
men. We divided our patients into two groups: those with CA19-9
> 100 and those with CA19-9 < 100. Among 6 patients with high
CA19-9, 5 had residual tumour in the explant specimen and all
developed recurrent disease and died. Just 1 patient in this group
remains alive and disease free (with no tumour in the explant
specimen) at 17 months after OLT. Among 8 patients with low
CA19-9 levels, no patient had a residual tumour in the explant
specimen and 7 of these 8 patients are alive and disease free, the
eighth patient having died as a hospital mortality. The Mayo
Clinic group also found that the presence of a tumour in the
explant specimen and an elevated CA 19-9 level had a negative
impact on outcome. Other factors which they identified as having
a negative effect included older age, prior cholecystectomy,
perineural spread and advanced tumour grade.15
There exists considerable controversy around whether it is jus-
tifiable to use donor livers (a scarce resource) for the treatment
of unresectable cholangiocarcinoma. This controversy could be
addressed from the perspective of a liver transplant surgeon or
from the perspective of a surgical oncologist. From a liver trans-
plant surgeon’s perspective, our results would certainly constitute
a ‘borderline’ indication for OLT. However, the results are at least
as good as results for other ‘borderline’ indications such as
patients who are co-infected with Hepatitis C plus HIV.20,21 From
a surgical oncologist’s perspective, there is no controversy: these
results are far superior to the results of a surgical resection and
these results were achieved in patients with unresectable disease.
Indeed, the Mayo Clinic group are now understandably making
the case for ‘Mayo Protocol’ plus OLT for patients with resectable
hilar CCA.18,22
In conclusion, we have not been able to reproduce the excellent
results achieved by the Mayo Clinic. However, we have shown that
a carefully selected group of patients, all with a definite diagnosis
of cholangiocarcinoma, can achieve very worthwhile survival
results: results which are certainly better than most published
results for surgical resection. We believe that this approach is
worthy of ongoing evaluation and we encourage a European
cooperative evaluation.23
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